About Curi Bio
Curi Bio is a company based in Seattle (United States) founded in 2015 by Elliot Fisher. Curi Bio has raised $26 million across 12 funding rounds from investors including NIH, HHS and UTC Investment. The company has 38 employees. Curi Bio has completed 1 acquisition, including Dana Solutions. Curi Bio offers products and services including Mantarray Platform and Curi Engine Services.
- Headquarter Seattle, United States
- Employees 38
- Founders Elliot Fisher
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website curibio.com
- Social LinkedIn X Facebook
- Legal Name Curi Bio
- Total Equity Funding$26M (USD)
in 12 rounds
- Latest Funding Round$10M (USD), Series B
Dec 2025
- InvestorsNIH
& 6 more
- Employee Count38
- Investments & Acquisitions
Products & Services of Curi Bio
Curi Bio offers a comprehensive portfolio of products and services, including Mantarray Platform and Curi Engine Services.
Used for 3D tissue contractility analysis to generate human-relevant data in drug safety assessments
Employed for preclinical drug development workflows involving disease models and analytical insights
Funding Insights of Curi Bio
Curi Bio has successfully raised a total of $26M across 12 strategic funding rounds. The most recent funding activity was a Series B round of $10 million completed in December 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $26M
- Total Rounds 12
- Last Round Series B — $10M
- First Round $1.96M
(Sep 2016)
- Investors Count 7
Latest 10 of 12 funding rounds of Curi Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2025 | $10M | Series B | – | Dream CIS | – |
| Dec 2023 | $2.31M | Grant | – | – | |
| Aug 2023 | $4.4M | Grant | – | – | |
| Dec 2022 | $2.26M | Grant | – | – | |
| Dec 2021 | $10M | Series A | – | Dynamk Capital | |
| Mar 2021 | $6M | Series A | – | Dynamk Capital | – |
| Aug 2020 | $252,131 | Grant | – | – | |
| Sep 2019 | $221,713 | Grant | – | – | |
| Sep 2019 | $1.97M | Grant | – | – | |
| May 2019 | $225,000 | Grant | – | – |
7 investors in total: 7 institutional.
Investors in Curi Bio
Curi Bio has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, HHS and UTC Investment.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital and private equity investment firm | – | utc.co.kr | Seoul, South Korea | |
Investment in life sciences innovation is facilitated by Dynamk Capital. | – | dynamk.vc | New York, United States | |
- | – | cascadiaventureforum.com | - | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
DS Asset is engaged in asset management and investment services. | – | dsasset.com | Seoul, South Korea | |
Provider of clinical research services | – | dreamcis.com | - |
Investor details for Curi Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Curi Bio
26 people are tracked at Curi Bio (5 in leadership, 7 in board & advisors, 14 in team); the tracked headcount is 38.
| Name | Role | Group |
|---|---|---|
Elliot Fisher | Co-Founder | Leadership |
Nicholas Geisse | CEO | Leadership |
Greg Luerman | VP, Research & Partnerships | Leadership |
Bryan Koci | Director Of Discovery Solutions | Leadership |
Shawn McGuire | Director, Engineering / Vp, Technology | Leadership |
Alec S.T. Smith | Chief Scientific Advisor | Board & advisors |
David Mack | Scientific Advisor | Board & advisors |
Hannele Ruohola-Baker | Scientific Advisor | Board & advisors |
Nate Sniadecki | Scientific Advisor | Board & advisors |
Jay Guo | Scientific Advisor | Board & advisors |
Leslie Tung | Scientific Advisor | Board & advisors |
Deok-Ho Kim | Advisor | Board & advisors |
Tanner P. | Software Engineer | Team |
Arjun Acharya | Biosystems Product Development Engineer | Team |
Bethany Ruffino | Project Manager - Scientific Services | Team |
Katharina G. | Data Science Associate | Team |
Arefin Ayesha | Scientist | Team |
Daniel Lih | Scientist | Team |
Aster Schmidt | Lead Firmware Engineer | Team |
Kevin Gray | Lead R&d Engineer | Team |
6 more people are available in the full profile.
Complete people profiles for Curi Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Curi Bio
Curi Bio has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Dana Solutions.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
AI platforms for cellular and tissue analysis are developed. | danasolutionsllc.com | Palo Alto, United States | 2018 | Jul 2020 | •••• |
Complete acquisition details for Curi Bio
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Curi Bio
4 dated milestones of Curi Bio across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Curi Bio is founded.
- Funding First funding round of $2.0M.
- Acquisition Acquires Dana Solutions.
- Funding Latest funding round, Series B, of $10.0M.
Web traffic of Curi Bio
The website of Curi Bio (curibio.com) receives about 7K visits a month.
- Monthly visits7K
▲ 36.3% vs previous month
Websites whose visitors overlap most with Curi Bio. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| cyrusbio.com | 100% | 1.9K | #9,105,938 | View details | |
| parsebiosciences.com | 87% | 62.7K | #493,988 | View details | |
| emulatebio.com | 82% | 35.5K | #945,229 | View details | |
creative-biolabs.com | creative-biolabs.com | 81% | – | #348,062 | – |
| upmbiomedicals.com | 80% | – | – | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 13 similar websites and full traffic analytics for Curi Bio
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 13 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Similar companies to Curi Bio
10 companies that operate in the same segment as Curi Bio (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Curi Bio
Curi Bio was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Curi Bio is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Nicholas Geisse is the current CEO of Curi Bio.
Curi Bio is a funded company, having raised a total of $26M across 12 funding rounds to date. The company's 1st funding round was a Grant of $225K, raised on Sep 2016.
Curi Bio has 38 employees.
Curi Bio was established in 2015 in Seattle, United States, within the biotechnology sector. Pharmaceutical products targeting various therapeutic areas are developed and manufactured by the company. Operations focus on drug production across multiple medical fields. Leadership is held by Co-Founder Elliot Fisher and CEO Nicholas Geisse, with activities centered in the U.S. geographic region.
Curi Bio offers Mantarray Platform and Curi Engine Services.
Curi Bio has made 1 acquisition, including Dana Solutions.
Curi Bio has 7 investors. Key investors include NIH, HHS, UTC Investment, DS Asset, and Dynamk Capital.
Curi Bio operates through Curi Bio.